{
  "nctId": "NCT07178743",
  "briefTitle": "Emulation of the PALOMA-2 Trial",
  "officialTitle": "Emulation of the PALOMA-2 Trial",
  "protocolDocument": {
    "nctId": "NCT07178743",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2025-08-18",
    "uploadDate": "2025-09-11T10:38",
    "size": 2806356,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT07178743/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 6097,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2025-07-14",
    "completionDate": "2025-10",
    "primaryCompletionDate": "2025-10",
    "firstSubmitDate": "2025-09-08",
    "firstPostDate": "2025-09-17"
  },
  "eligibilityCriteria": {
    "criteria": "Study Period:\n\nENCORE database 1 (EDB1): Patient identification period: 01/01/2011-04/30/2024 with follow-up information through data cut-off date on 04/30/2024\n\nENCORE database 3 (EDB3): Follow-up information through June 2023 (there is no specific time period restrictions for patient eligibility)\n\nENCORE database 4 (EDB4): Patient identification period: 10/01/2018-09/30/2023 with follow-up information through data cut-off date on 09/30/2023.\n\nInclusion Criteria:\n\n* Age â‰¥18 years\n* Postmenopausal women with ER-positive, HER2-negative locally advanced or metastatic breast cancer who receive treatment without curative intent\n* The line of therapy for patients in EDB1 and EDB3 is implicitly advanced/metastatic because the line of therapy classification starts after their advanced/metastatic diagnosis in the respective database\n* In EDB4, patients must explicitly have any evidence of a metastasis prior initiating palbociclib plus letrozole or letrozole alone\n* Adenocarcinoma histology\n* No prior systemic treatment for advanced/metastatic disease\n* ECOG performance status of 0 or 1\n\nExclusion Criteria:\n\n* HER2+\n* CNS metastases\n* Prior treatment with CDK4/6 inhibitor\n* Non-breast cancer malignancy other than basal/squamous cell skin cancer or carcinoma in situ of cervix\n* Systemic anticancer therapy other than palbocicilib or letrozole\n* Treatment with non-steroidal aromatase inhibitor (i.e.anastrozole, letrozole)",
    "healthyVolunteers": false,
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Time to all-cause mortality (overall survival)",
        "description": "Hazard ratio (95% CI)",
        "timeFrame": "Through the earliest of outcome, censoring, or end of data (April 2024)"
      }
    ],
    "secondary": [
      {
        "measure": "Time to next treatment (TTNT)",
        "description": "Median overall survival time (difference) in % (95% CI)",
        "timeFrame": "Through the earliest of outcome, censoring, or end of data (April 2024)"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 0,
      "exclusionCount": 0,
      "totalCount": 0
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 30,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T05:06:11.775Z",
  "dataSource": "ClinicalTrials.gov API v2 - Ultimate Complete Collection"
}